Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will determine the overall response rate and toxicity of rituximab and Velcade in combination in patients with relapsed or refractory mantle cell non-Hodgkin's lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ohio State University Comprehensive Cancer Center
• Treatments: Bortezomib; Rituximab

Criteria

Inclusion Criteria:

• Histologically confirmed mantle cell or follicular lymphoma

• Relapsed or refractory disease

• ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1, 2 or 3

Exclusion Criteria:

• Pre-existing sensory or motor peripheral neuropathy

• No active or untreated CNS (Central Nervous System) lymphoma

• History of severe, life-threatening hypersensitivity or infusion reactions prior rituximab treatment.